8-K: Evolus Reports Strong Q4, Full-Year 2025 Revenue Growth

Evolus, Inc. announced preliminary unaudited net revenue for Q4 and full-year 2025, projecting continued double-digit growth and reaffirming 2026 profitability.

Summary

• Preliminary unaudited net revenue for the fourth quarter of 2025 is expected to be between $88.6 million and $90.6 million, representing 12% to 15% growth over the prior year.
• The company reaffirms positive non-GAAP operating income of $5 million to $7 million for Q4 2025.
• Preliminary unaudited net revenue for the full-year 2025 is expected to be between $295.5 million and $297.5 million, representing 11% to 12% growth over the prior year.
• Evolysse injectable hyaluronic acid (HA) gels contributed approximately 8% of total revenue for the full-year 2025.
• Cash and cash equivalents stood at $53 million as of December 31, 2025, an increase from $43.5 million on September 30, 2025.
• 2026 net revenue guidance is set between $327.0 million and $337.0 million, reflecting 11% to 13% growth from preliminary unaudited 2025 results.
• Evolysse and Estyme injectable HA gels are anticipated to contribute 10% to 12% of total revenue for the full-year 2026.
• The company expects to achieve sustainable annual profitability beginning in 2026.
• The 2028 long-term financial outlook has been updated to reflect total net revenue of $450 million to $500 million, representing a three-year CAGR of 15% to 19%, and non-GAAP operating income margins of 13% to 15%.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth, achievement of profitability, and positive future guidance, despite acknowledging a conservative market outlook. The increase in cash and continued double-digit growth are strong positives, though the delay in Evolysse Sculpt revenue is a minor negative.

Positives

• Achieved its sixth consecutive year of double-digit growth in 2025.
• Reaffirmed positive non-GAAP operating income of $5 million to $7 million for Q4 2025, marking a pivotal achievement of profitability.
• Increased cash and cash equivalents to $53 million by December 31, 2025, up from $43.5 million on September 30, 2025, reflecting strong sales growth and prudent expense management.
• Successfully diversified its business through the introduction of a second product line (Evolysse HA gels) and accelerated international expansion.
• Maintains projection for sustainable annual profitability beginning in 2026.
• Updated 2028 long-term financial outlook projects robust revenue growth (15% to 19% CAGR) and significant non-GAAP operating income margin expansion (13% to 15%).

Negatives

• The updated 2028 long-term financial outlook reflects a recalibrated U.S. market outlook, indicating a more conservative near-term growth environment.
• No revenue contribution is anticipated from Evolysse Sculpt in 2026, as regulatory approval is not expected until the fourth quarter of 2026.

Risks

• Uncertainties associated with the ability to comply with the terms and conditions in the Medytox Settlement Agreements.
• Ability to fund future operations or obtain financing to fund operations.
• Unfavorable global economic conditions, including trade disputes and tariffs, and their impact on consumer discretionary spending.
• Uncertainties related to customer and consumer adoption of Jeuveau and Evolysse.
• The efficiency and operability of the digital platform.
• Competition and market dynamics.
• Ability to successfully launch and commercialize products in new markets, including Evolysse Hyaluronic Acid (HA) gels in the U.S. and Estyme HA gels in Europe.
• Ability to maintain regulatory approvals of Jeuveau and Evolysse or obtain regulatory approvals for new product candidates or indications.
• Reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse HA gel products in the U.S.
• Preliminary estimates of unaudited financial results may differ materially from actual results.

Future Outlook

Evolus projects 2026 net revenue between $327 million and $337 million, targeting 11% to 13% growth, and expects to achieve sustainable annual profitability starting in 2026. The long-term financial outlook for 2028 anticipates total net revenue of $450 million to $500 million with non-GAAP operating income margins of 13% to 15%, driven by continued market share gains, portfolio expansion, and international growth, despite a more conservative near-term U.S. market outlook.

Management Comments

• "The preliminary results for the fourth quarter and full-year 2025 highlight our sixth consecutive year of double-digit growth and demonstrate our ability to continue gaining market share in a challenging environment."
• "Last year was pivotal for Evolus as we further diversified our business through the introduction of our second product line, accelerated our international expansion, and delivered strong commercial execution across our portfolio. These efforts reinforced the strength of our performance beauty strategy and enabled us to achieve profitability in the fourth quarter of 2025."
• "Our 2026 outlook reflects a measured return to market growth as we continue to increase penetration in the U.S. and expand our portfolio internationally. Our growth outlook and disciplined spend will drive improved profitability as we scale."
• "We have recalibrated our long-term financial targets to reflect growing market share against a more conservative market growth outlook, while maintaining our confidence in our ability to continue to deliver above-market growth and meaningful profitability going forward. Importantly, this outlook assumes a return to more normalized market growth conditions over time."
• "With a growing customer base and scalable global infrastructure, we believe we are well-positioned to drive durable growth and long-term value creation."

Industry Context

The company acknowledges a "challenging environment" and a "more conservative near-term growth environment" in the U.S. market, suggesting broader industry headwinds. Despite this, Evolus aims to gain market share and achieve above-market growth through portfolio diversification (HA gels) and international expansion, indicating a strategic focus on outperforming a potentially slower overall market for aesthetic injectables.

Comparison to Industry Standards

• NA

Legal Proceedings

• Uncertainties associated with the ability to comply with the terms and conditions in the Medytox Settlement Agreements.

Stakeholder Impact

• Shareholders: Positive preliminary financial results, strong growth projections, and expected profitability could lead to increased investor confidence and potential share price appreciation.
• Employees: Continued growth, market share gains, and international expansion suggest stability and potential opportunities for career development.
• Customers: Expansion of the product portfolio with Evolysse and Estyme HA gels, along with international reach, offers more choices and accessibility to aesthetic treatments.
• Creditors: Improved cash position and projected profitability enhance the company's financial health and ability to meet its obligations.

Next Steps

• Completion of the audit of the company's 2025 financial results.
• Reporting of full financial results for the fourth quarter and full-year 2025, anticipated in early March 2026.
• U.S. commercialization of Evolysse Form and Evolysse Smooth.
• Anticipated commercial launch of Estyme in Europe.
• Anticipated regulatory approval for Evolysse Sculpt in the fourth quarter of 2026.

Key Dates

Recommendation

The company demonstrates consistent double-digit revenue growth, has achieved non-GAAP operating profitability in Q4 2025, and projects sustainable annual profitability starting in 2026. Its strategic diversification into HA gels and international expansion are driving market share gains despite a conservative market outlook. The strong cash position and positive long-term guidance for 2028, with significant revenue and margin expansion, indicate a robust growth trajectory and strong value creation potential for investors. The minor delay in Evolysse Sculpt is offset by overall strong performance and strategic execution.

Keywords

Evolus, EOLS, Preliminary Revenue, Financial Guidance, Aesthetics, Neurotoxin, Hyaluronic Acid Gels, Jeuveau, Evolysse, Estyme, Profitability, Market Share, International Expansion, Performance Beauty